{
  "type": "article",
  "title": "Three Patients Become the First Humans to Receive Coherence Neuro's Tumor-Sensing Brain Implant",
  "summary": "During tumor removal surgeries at the Royal Melbourne Hospital in Australia, Coherence Neuro temporarily placed its coin-sized brain implant in three patients for roughly 30 minutes, marking the device's debut in humans as the company prepares for permanent implantation trials.",
  "content": "Three people undergoing surgery to have brain tumors removed at the Royal Melbourne Hospital in Australia have become the first humans to receive Coherence Neuro's electronic brain implant. The coin-sized device sat inside each patient's skull for roughly 30 minutes during the procedure before being taken out, giving the startup a critical window to observe how the implant performs in a live surgical setting. All three patients had given their consent before the operations began.\n\nWhat the Device Is Designed to Do\nThe Coherence Neuro implant is a brain-computer interface. When permanently placed, it sits inside the skull with 16 thin threads that extend into the surrounding brain tissue. The device is built to do two things simultaneously: detect the distinctive electrical signals that tumor cells produce, and deliver mild electrical stimulation designed to prevent tumor growth. The intent is to install it during a brain tumor resection, the surgery in which a tumor is removed, so patients avoid a separate procedure entirely. Even after a tumor is fully removed, recurrence is common, and the Coherence device is specifically designed to monitor for and guard against that possibility.\n\nThe Science of Using Electricity Against Brain Cancer\nThe reasoning behind electrical stimulation as a cancer treatment draws on decades of research. Tumor tissue differs from healthy brain tissue in measurable electrical ways, and scientists have long believed that property could be turned into a therapeutic lever. Ben Woodington, the chief executive officer and cofounder of Coherence, frames the logic this way: \"These are electrical conditions, just like epilepsy, just like depression. This is a network problem in the brain.\"\n\nA pivotal piece of evidence arrived in 2019, when researchers at Stanford University demonstrated that a class of particularly dangerous brain tumors called high-grade gliomas actively drive their own spread by forming synapses directly with healthy neurons. That same study showed that administering a seizure drug to mice cut off the electrical signals feeding the tumor and slowed its growth. Additional research has separately shown that low-intensity electrical current can disrupt cancer cell division in brain tumors.\n\nAn Existing Treatment and Its Real-World Drawbacks\nUsing electricity against brain tumors already has a commercial history. A wearable device called Optune, developed by Novocure, received its first regulatory approval in 2011 to treat adults with glioblastoma, a type of brain cancer that makes up roughly half of all cancerous brain tumors. Earlier this year, Novocure also received regulatory approval to extend the Optune device to pancreatic cancer, with the device attached either to the scalp or the stomach via adhesive patches depending on which cancer is being treated.\n\nOptune can extend survival by several months, but only when worn for most of the day. To use it, patients must shave their heads and carry a battery pack in a backpack or strapped to a hip belt. Coherence's central argument is that a device tucked permanently inside the skull delivers comparable or superior therapy without any of that daily burden.\n\nThe Notable People Backing the Company\nCoherence Neuro has drawn in prominent names from neurotechnology. Matthew MacDougall, who serves as head neurosurgeon at Neuralink, is both an adviser and an investor in Coherence. Rory Murphy, a neurosurgeon at the Barrow Neurological Institute in Arizona who serves as an investigator in one of Neuralink's clinical trials, is also expected to participate in future Coherence trials.\n\nWhy Glioblastoma, and How Bleak the Outlook Is\nCoherence is initially targeting glioblastoma because it carries a higher likelihood of returning after surgery compared to lower-grade tumors. Patients diagnosed with glioblastoma have few treatment options and a grim prognosis. Most survive only 15 to 18 months after diagnosis, and the five-year survival rate sits below 10 percent. The current standard of care calls for an MRI scan every two to three months so clinicians can monitor tumor activity and adjust medications as needed.\n\nWoodington argues that interval is far too long. A tumor can become dramatically more aggressive between scans, and doctors have no visibility into what is happening during those gaps. The Coherence device is built to close that blind spot through continuous monitoring. A companion app lets patients log their symptoms, and that information is transmitted to their care team alongside data on their disease state and the level of stimulation the device is delivering. Physicians can fine-tune the therapy remotely, or allow the implant to self-regulate automatically. The device could also detect a rapid spike in tumor activity and prompt doctors to consider surgical intervention before the next scheduled MRI would ever flag the change.\n\nWhat Comes Next for Coherence\nWith the brief in-surgery placement confirmed as safe and technically feasible, Coherence Neuro plans to launch a new trial next year in which glioblastoma patients will receive the implant on a permanent basis. That trial will produce the longer-term safety and efficacy data the company needs before it can seek broader regulatory clearance for the device.\n\nWhat this means for you\n• For brain cancer patients: If Coherence Neuro's implant clears future trials, glioblastoma patients could move from MRI check-ins every two to three months to around-the-clock monitoring, catching dangerous tumor changes far earlier than current methods allow.\n• For daily quality of life: Unlike Optune, which requires shaving the head and carrying a battery pack every single day, a permanently implanted device would let patients live without any external wearable equipment.\n\nQuestions & Answers\n\n1. What is Coherence Neuro's brain implant and how does it work?\nIt is a brain-computer interface that sits inside the skull with 16 thin threads extending into brain tissue. It detects the unique electrical signals produced by tumor cells and delivers mild electrical stimulation designed to slow or stop tumor growth.\n\n2. Where was this trial conducted and who were the patients?\nThe trial took place at the Royal Melbourne Hospital in Australia. Three patients already undergoing surgery to have brain tumors removed had the implant placed inside their skulls for roughly 30 minutes before it was taken out.\n\n3. How dangerous is glioblastoma?\nIt is among the deadliest forms of brain cancer. Most patients survive only 15 to 18 months after diagnosis, and the five-year survival rate is less than 10 percent.\n\n4. How does the Coherence device differ from Optune?\nOptune is an external wearable that requires patients to shave their heads and carry a battery pack in a backpack or on a hip belt every day. The Coherence implant sits permanently inside the skull, with no external equipment required.\n\n5. What is Neuralink's connection to this project?\nMatthew MacDougall, Neuralink's head neurosurgeon, is both an adviser and an investor in Coherence Neuro. Rory Murphy, a neurosurgeon at the Barrow Neurological Institute in Arizona and an investigator in a Neuralink trial, is also expected to participate in future Coherence trials.\n\n6. What did the 2019 Stanford University study show?\nResearchers found that high-grade gliomas drive their own growth by forming synapses with healthy neurons, and that giving a seizure drug to mice interrupted those electrical signals and slowed tumor progression.\n\n7. How will the device help doctors manage patients between MRI appointments?\nThe device continuously monitors brain activity and feeds data to a companion app that forwards it to clinicians. Doctors can remotely adjust the electrical therapy or let the implant self-regulate, and it can flag sudden tumor acceleration before the next MRI would catch it.\n\n8. What are Coherence Neuro's next steps?\nThe company plans to begin a new trial next year in which glioblastoma patients will receive the implant on a permanent basis, generating the long-term data needed to pursue broader regulatory clearance.",
  "url": "https://trendkia.com/en/health/coherence-neuro-ka-dimagi-implanta-australia-men-tina-marijon-para-hua-pahala-saphala-trayala-2451",
  "category": "Health",
  "publishedAt": "2026-06-23",
  "tags": [
    "Brain Implant",
    "Glioblastoma",
    "Coherence Neuro",
    "Brain Tumor Treatment",
    "Electrical Stimulation",
    "Neuralink",
    "Brain Computer Interface",
    "Cancer Technology"
  ],
  "language": "en",
  "site": "TrendKia"
}